JP2021516537A5 - - Google Patents
Info
- Publication number
- JP2021516537A5 JP2021516537A5 JP2020543219A JP2020543219A JP2021516537A5 JP 2021516537 A5 JP2021516537 A5 JP 2021516537A5 JP 2020543219 A JP2020543219 A JP 2020543219A JP 2020543219 A JP2020543219 A JP 2020543219A JP 2021516537 A5 JP2021516537 A5 JP 2021516537A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1803892.7 | 2018-03-12 | ||
| GBGB1803892.7A GB201803892D0 (en) | 2018-03-12 | 2018-03-12 | C-met binding agents |
| GB1812487.5 | 2018-07-31 | ||
| GBGB1812487.5A GB201812487D0 (en) | 2018-03-12 | 2018-07-31 | C-Met binding agents |
| GBGB1816841.9A GB201816841D0 (en) | 2018-03-12 | 2018-10-16 | C-met binding agents |
| GB1816841.9 | 2018-10-16 | ||
| PCT/EP2019/056178 WO2019175186A1 (en) | 2018-03-12 | 2019-03-12 | Anti c-met antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516537A JP2021516537A (ja) | 2021-07-08 |
| JP2021516537A5 true JP2021516537A5 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| JP7458567B2 JP7458567B2 (ja) | 2024-04-01 |
Family
ID=61972884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543219A Active JP7458567B2 (ja) | 2018-03-12 | 2019-03-12 | C-met結合剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11673960B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3765509A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7458567B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111819200B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019233511B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092526A1 (cg-RX-API-DMAC7.html) |
| GB (3) | GB201803892D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019175186A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| IL296519A (en) * | 2020-06-02 | 2022-11-01 | Teijin Pharma Ltd | Anti-igf-1 receptor humanized antibody |
| JP7510518B2 (ja) * | 2020-09-01 | 2024-07-03 | レメゲン シーオー.,エルティーディー. | 抗c-Met抗体薬物複合体及びその応用 |
| EP4232087A4 (en) * | 2020-10-21 | 2024-10-09 | Immune-ONC Therapeutics, Inc. | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS |
| AR125473A1 (es) * | 2021-04-29 | 2023-07-19 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
| CN115724970B (zh) * | 2022-07-27 | 2023-10-20 | 生工生物工程(上海)股份有限公司 | 一种特异性结合e-cad多肽的结合蛋白及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2383295T3 (en) * | 2003-12-10 | 2015-06-15 | Squibb & Sons Llc | Ip-10 antibodies and uses thereof |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US20140112911A9 (en) | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| BRPI1015234A2 (en) * | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| HK1201855A1 (en) * | 2011-11-01 | 2015-09-11 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| TWI593705B (zh) * | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| CN104321322A (zh) * | 2012-03-30 | 2015-01-28 | 理森制药股份公司 | 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物 |
| CA2869316C (en) * | 2012-05-09 | 2016-12-20 | Eli Lilly And Company | Anti-c-met antibodies |
| CN106458916A (zh) * | 2014-03-11 | 2017-02-22 | 西奈山伊坎医学院 | 受限制的三环磺酰胺 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
-
2018
- 2018-03-12 GB GBGB1803892.7A patent/GB201803892D0/en not_active Ceased
- 2018-07-31 GB GBGB1812487.5A patent/GB201812487D0/en not_active Ceased
- 2018-10-16 GB GBGB1816841.9A patent/GB201816841D0/en not_active Ceased
-
2019
- 2019-03-12 AU AU2019233511A patent/AU2019233511B2/en active Active
- 2019-03-12 CN CN201980017468.2A patent/CN111819200B/zh active Active
- 2019-03-12 CN CN202410570377.4A patent/CN118459588A/zh active Pending
- 2019-03-12 WO PCT/EP2019/056178 patent/WO2019175186A1/en not_active Ceased
- 2019-03-12 CA CA3092526A patent/CA3092526A1/en active Pending
- 2019-03-12 US US16/980,015 patent/US11673960B2/en active Active
- 2019-03-12 EP EP19711070.3A patent/EP3765509A1/en active Pending
- 2019-03-12 JP JP2020543219A patent/JP7458567B2/ja active Active
-
2023
- 2023-04-21 US US18/304,598 patent/US12415861B2/en active Active
-
2025
- 2025-08-19 US US19/304,080 patent/US20260042850A1/en active Pending
-
2026
- 2026-04-10 AU AU2026202717A patent/AU2026202717A1/en active Pending